Lees-Rolfe Garth 4
4 · Inhibikase Therapeutics, Inc. · Filed Jan 22, 2025
Insider Transaction Report
Form 4
Lees-Rolfe Garth
Chief Financial Officer
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2025-01-21−5,834→ 0 totalExercise: $3.79Exp: 2029-11-28→ Common Stock (5,834 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-01-21−90,000→ 0 totalExercise: $2.16Exp: 2031-04-01→ Common Stock (90,000 underlying) - Award
Stock Option (Right to Buy)
2025-01-21+90,000→ 90,000 totalExercise: $1.26Exp: 2031-04-01→ Common Stock (90,000 underlying) - Award
Stock Option (Right to Buy)
2025-01-21+5,834→ 5,834 totalExercise: $1.26Exp: 2029-11-28→ Common Stock (5,834 underlying)
Footnotes (2)
- [F1]The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
- [F2]This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.